Andersen-Tawil syndrome (ATS) is a rare inherited autosomal disorder characterized by the clinical triad of ventricular arrhythmias, hypokalaemic periodic paralyses, and skeletal developmental abnormalities, resulting in dysmorphic features. Although ATS patients have a high incidence of ventricular arrhythmias, the occurrence of sudden cardiac death is rare. In this report, we describe the successful use of flecainide in an ATS patient with a considerable ventricular arrhythmia burden who had not demonstrated any response to conventional β-blocker therapy used in conjunction with potassium (K +) supplementation. © The Author 2008.
CITATION STYLE
Fox, D. J., Klein, G. J., Hahn, A., Skanes, A. C., Gula, L. J., Yee, R. K., … Krahn, A. D. (2008). Reduction of complex ventricular ectopy and improvement in exercise capacity with flecainide therapy in Andersen-Tawil syndrome. Europace, 10(8), 1006–1008. https://doi.org/10.1093/europace/eun180
Mendeley helps you to discover research relevant for your work.